ResearcherFudan UniversityActive in the last 2 years

Yazhou Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0615-5567; OpenAlex author ID A5101476789. Sources: OpenAlex.

Their work

Papers: 4 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 12

Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 4

First reported advanced pancreatic cancer with hyperprogression treated with PD-1 blockade combined with chemotherapy: a case report and literature review. Co-author DOI 10.1007/s12672-024-01420-3 ↗
Inhibition of bone morphogenetic protein receptor 2 suppresses pancreatic ductal adenocarcinoma growth by regulating GRB2/PI3K/AKT axis. Co-author DOI 10.21037/atm-20-2194 ↗
High mobility group AT-hook 2 promotes tumorigenicity of pancreatic cancer cells via upregulating ANLN. First author DOI 10.1016/j.yexcr.2020.112088 ↗
Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer … Co-author DOI 10.1021/acsnano.8b01573 ↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Huahu Guo · 2 shared papers, 2020–2021 · strength 0.29
- Paper Inhibition of bone morphogenetic protein receptor 2 suppresses pancreatic ductal adenocarcinoma growth by regulating GR… DOI 10.21037/atm-20-2194 ↗
- Paper High mobility group AT-hook 2 promotes tumorigenicity of pancreatic cancer cells via upregulating ANLN. DOI 10.1016/j.yexcr.2020.112088 ↗
Zhengkui Zhang · 2 shared papers, 2018–2021 · strength 0.22
- Paper Inhibition of bone morphogenetic protein receptor 2 suppresses pancreatic ductal adenocarcinoma growth by regulating GR… DOI 10.21037/atm-20-2194 ↗
- Paper Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Tre… DOI 10.1021/acsnano.8b01573 ↗
Huaxiang Xu · 1 shared paper, 2024 · strength 0.22
- Paper First reported advanced pancreatic cancer with hyperprogression treated with PD-1 blockade combined with chemotherapy: … DOI 10.1007/s12672-024-01420-3 ↗
Wenquan Wang · 1 shared paper, 2024 · strength 0.22
- Paper First reported advanced pancreatic cancer with hyperprogression treated with PD-1 blockade combined with chemotherapy: … DOI 10.1007/s12672-024-01420-3 ↗
Xiaodong Tian · 2 shared papers, 2018–2020 · strength 0.20
- Paper High mobility group AT-hook 2 promotes tumorigenicity of pancreatic cancer cells via upregulating ANLN. DOI 10.1016/j.yexcr.2020.112088 ↗
- Paper Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Tre… DOI 10.1021/acsnano.8b01573 ↗
Yinmo Yang · 1 shared paper, 2021 · strength 0.16
- Paper Inhibition of bone morphogenetic protein receptor 2 suppresses pancreatic ductal adenocarcinoma growth by regulating GR… DOI 10.21037/atm-20-2194 ↗
Xiaodong Tian · 1 shared paper, 2021 · strength 0.16
- Paper Inhibition of bone morphogenetic protein receptor 2 suppresses pancreatic ductal adenocarcinoma growth by regulating GR… DOI 10.21037/atm-20-2194 ↗
Yinmo Yang · 1 shared paper, 2020 · strength 0.13
- Paper High mobility group AT-hook 2 promotes tumorigenicity of pancreatic cancer cells via upregulating ANLN. DOI 10.1016/j.yexcr.2020.112088 ↗
Yinmo Yang · 1 shared paper, 2018 · strength 0.07
- Paper Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Tre… DOI 10.1021/acsnano.8b01573 ↗
Chong Du · 1 shared paper, 2018 · strength 0.07
- Paper Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Tre… DOI 10.1021/acsnano.8b01573 ↗
Xiao Zhao · 1 shared paper, 2018 · strength 0.07
- Paper Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Tre… DOI 10.1021/acsnano.8b01573 ↗
Guangjun Nie · 1 shared paper, 2018 · strength 0.07
- Paper Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Tre… DOI 10.1021/acsnano.8b01573 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.